Thymmune
Developer of immunetherapeutics for immune-disorders
📍 Cambridge, United States · Immunotherapy
Funding snapshot
Last roundSeed
Amount$3M
Date28 April 2025
About
Developer of immunetherapeutics for immune-disorders. It offers iPSC-derived thymic cells -based therapeutics to restore normal immune function and treat immunodeficiencies, transplant-related, and autoimmune disorders.
Latest news
No articles yet.
Similar startups
PayFlow
Embedded payments infrastructure for Southeast Asian marketplaces and platforms.
GreenGrid
Software for planning and operating distributed battery storage across Europe.
Immuneel
Developer of T-cell therapies for the treatment of cancer
ImmunoACT
Developer of cell and gene therapies for cancer treatment